Light-Based Cancer Biomarker Sensor Catches Early Signals

A new light-based cancer biomarker sensor can spot trace cancer signals in blood at sub-attomolar levels. Built at Shenzhen University in China, it flagged lung cancer markers in patient serum without chemical amplification.

The work appeared in Optica. A routine blood draw could catch early cancer signs well before a tumor shows on a CT scan.

Why early biomarker detection matters

Biomarkers in blood — proteins, DNA fragments, microRNAs — can flag whether cancer is there, how it is moving, or someone's odds. The trouble is timing. In early disease, these markers sit at low concentrations. Standard tools can miss them.

By the time imaging finds a tumor, the disease may already be advanced. The light-based cancer biomarker sensor aims to close that gap. It pairs DNA nanostructures, quantum dots, and CRISPR gene editing into one optical readout.

"Our sensor combines nanostructures made of DNA with quantum dots and CRISPR gene editing technology to detect faint biomarker signals using a light-based approach known as second harmonic generation (SHG)," said Han Zhang, the team leader at Shenzhen University.

Zhang said the design could help simplify treatment, raise survival rates, and trim healthcare costs.

How second harmonic generation works here

The sensor uses second harmonic generation (SHG), a nonlinear optical effect. Photons hitting the surface emerge at half their wavelength. SHG runs on the surface of molybdenum disulfide (MoS₂), a two-dimensional semiconductor.

The team built DNA tetrahedrons. These pyramid-shaped nanostructures, made entirely from DNA, hold quantum dots at set distances from the MoS₂ surface. They boost the local optical field and lift the SHG signal.

CRISPR-Cas adds the recognition step. When the Cas12a protein meets its target, it slices the DNA strands anchoring the quantum dots. That cut drops the SHG signal. SHG runs quiet, so faint biomarker levels rise above background noise.

"Instead of viewing DNA only as a biological substance, we use it as programmable building blocks, allowing us to assemble the components of our sensor with nanometer-level precision," Zhang said.

He added the amplification-free design gives the platform a distinct balance of speed and precision.

Why amplification-free matters

Most cancer biomarker tests need chemical amplification to boost tiny molecular signals. That step costs time, money, and complexity. It also opens room for error.

The light-based cancer biomarker sensor skips that step. It reads the molecular signal directly. Fewer steps mean faster results and lower bench costs.

Lung cancer testing in human serum

To test real-world value, the team focused on miR-21, a microRNA biomarker tied to lung cancer.

They first checked detection in a buffer solution. The light-based cancer biomarker sensor flagged miR-21 cleanly. Then they ran it on human serum from lung cancer patients. The result mimicked an actual blood test.

"The sensor worked exceptionally well, showing that integrating optics, nanomaterials and biology can be an effective strategy to optimize a device," Zhang said.

He added the sensor was highly specific, picking out the lung cancer target while ignoring other similar RNA strands.

Patient samples returned signals at sub-attomolar levels. That is far below the floor of most clinical assays. Even a handful of molecules produced a clear readout.

Beyond lung cancer: a programmable platform

The platform is programmable. By swapping CRISPR guide RNAs, the team could retune it to flag other targets.

Zhang's team listed viruses, bacteria, environmental toxins, and biomarkers tied to Alzheimer's disease. The same chassis could screen for many threats. One platform supporting many tests is cheaper to scale than one device per disease.

Zhang said early diagnosis is the headline use. A simple blood screen could flag lung cancer before a tumor appears on CT. Daily or weekly readouts could also track drug response.

Toward a portable bedside test

The current setup is lab-grade. The next step is shrinking the optical system. The team wants a portable version usable at bedside, in outpatient clinics, or in remote regions.

A handheld, amplification-free readout would widen access to early cancer testing. It could move screening into primary care offices and rural clinics. Other labs must verify the work, and trials in larger cohorts must follow.

The light-based cancer biomarker sensor could reshape how clinicians catch cancer early. Coverage on Medigear.uk shows why hospital teams must follow how the light-based cancer biomarker sensor findings shape oncology.

Source: Originating coverage based on Optica press materials on Han Zhang et al., light-based cancer biomarker sensor reported in Optica (Optica Publishing Group). Research led by Han Zhang, Shenzhen University, China. miR-21 microRNA target tested in human serum from lung cancer patients.